^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    favezelimab/pembrolizumab (MK-4280A)

    i
    Associations
    News

    Trials

    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (KEYMAKER-U04 Substudy) (NCT05845814)
    Phase 1/2
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/23/2023
    Primary completion :
    05/31/2027
    Completion :
    05/31/2027
    PD-L1
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (NCT04895722)
    Phase 2
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    06/25/2021
    Primary completion :
    10/20/2025
    Completion :
    11/18/2025
    MSI
    |
    MSI-H/dMMR • RAS wild-type
    |
    Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)
    A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (KeyImPaCT) (NCT03516981)
    Phase 2
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/26/2024
    Initiation :
    10/01/2018
    Primary completion :
    06/28/2025
    Completion :
    06/28/2025
    EGFR • ALK • ROS1
    |
    ALK rearrangement
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab (MK-4280) • quavonlimab (MK-1308) • favezelimab/pembrolizumab (MK-4280A)